US equities |
SPCX $166.84 ▲+4.96% NVDA $236.93 ▲+1.27% MU $1,064.60 ▼-0.96% TSLA $377.48 ▲+1.86% MSFT $526.42 ▲+1.72% SNDK $1,714.00 ▼-0.35% INTC $117.21 ▼-1.78% META $745.34 ▲+2.37%
FinancialContent

Cyclo Therapeutics, Inc. - Common Stock (NQ:CYTH)

0.7206 UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cyclo Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
42 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Sono Group N.V. (NASDAQ: SEV) shares jumped 66% to $24.90 after the company priced its IPO at $15 per share. EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) shares climbed... 
Via Benzinga
Topics Initial Public Offering
News headline image
Mid-Morning Market Update: Markets Down; Lowe's Earnings Beat Estimates ↗
Following the market opening Wednesday, the Dow traded down 0.34% to 36,017.63 while the NASDAQ fell 0.19% to 15,944.13. The S&P also fell, dropping 0.23% to 4,690.06. The U.S... 
Via Benzinga
Topics Earnings Stocks
News headline image
Cyclo Raises $12M Equity At 18% Discount To Fund Trappsol Development ↗
Cyclo Therapeutics Inc (NASDAQ: CYTH) has priced its previously announced underwritten public offering of 1.95 million shares at $6.00 per share, with gross proceeds of... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Gainers Rockwell Medical (NASDAQ:RMTI) shares rose 47.27% to $0.71 during Wednesday's pre-market session. The company's market cap stands at $66.5 million. The... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Atea Sinks On Termination Of Roche Contract, Pfizer CFO To Retire, GSK-Vir Bag $1B Contract To Supply COVID Antibody Treatment ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Atea Announces Termination of Strategic Collaboration With Roche Atea... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
Good morning, trader! We're halfway through the week and with that comes a look at the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
News headline image
25 Stocks Moving in Wednesday's Pre-Market Session ↗
Gainers 17 Education & Technology Group Inc. (NASDAQ: YQ) rose 283.5% to $3.16 in pre-market trading. 17 Education & Technology, earlier during the month, reported a $10... 
Via Benzinga
News headline image
A Peek Into The Markets: US Stock Futures Mixed Ahead Of Earnings, Fed Speakers ↗
Pre-open movers U.S. stock futures traded mixed in early pre-market trade after closing mostly flat in the prior session. Investors are awaiting earnings results from Lowe`s... 
Via Benzinga
Topics Economy
News headline image
5 Stocks To Watch For November 17, 2021 ↗
Some of the stocks that may grab investor focus today are: Wall Street expects Lowe`s Companies Inc (NYSE: LOW) to report quarterly earnings at $2.35 per share on revenue of $... 
Via Benzinga
News headline image
Cyclo Therapeutics Announces Pricing of $11.7 Million Underwritten Public Offering of Common Stock
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
Cyclo Therapeutics Announces Proposed Public Offering of Common Stock
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
Cyclo Therapeutics Shares Jump After Filing To Start Alzheimer's Trial In US ↗
Cyclo Therapeutics Inc (NASDAQ: CYTH) has submitted its initial investigational new drug (IND) application with the FDA for a Phase 2 study of Trappsol Cyclo for... 
Via Benzinga
News headline image
Cyclo Therapeutics Submits Investigational New Drug Application to U.S. FDA to Advance Trappsol® Cyclo™ in Phase 2 Study for Treatment of Alzheimer’s Disease
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
Cyclo Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
Cyclo Therapeutics to Present at the Virtual Investor Roundtable Event
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
JTC Team to Host Virtual Investor Roundtable Event on November 16th, 17th, and 18th
- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast roundtable discussions with members of Management and Thought Leaders across participating... 
From JTC Team, LLC
Via AccessWire
News headline image
Cyclo Therapeutics Names Preeminent Neuroscientist and World-Renowned Researcher, Cynthia A. Lemere, PhD, as Senior Advisor for Advancement of Alzheimer’s Disease Asset
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
Cyclo Therapeutics Recognizes Niemann-Pick Disease Awareness Month Highlighting Need for Broader Awareness and Support for Research to Find a Treatment
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the 14th International Congress of Inborn Errors of Metabolism (ICIEM)
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
Cyclo Therapeutics to Participate in the 2021 Virtual Cyclodextrin Conference Hosted by CycloLab
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
Cyclo Therapeutics Appoints Lise Lund Kjems, MD, PhD as Chief Medical Officer
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
Cyclo Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
Cyclo Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
Cyclo Therapeutics' Trappsol Shows Early Safety, Efficacy In Genetic Disorder ↗
Cyclo Therapeutics Inc (NASDAQ: CYTH) has announced new data from its Phase 1 extension study evaluating Trappsol Cyclo Niemann-Pick Disease Type C1 (NPC), a... 
Via Benzinga
News headline image
Cyclo Therapeutics Announces New Positive Safety and Efficacy Data from Ongoing Phase 1 Open-Label Extension Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
Cyclo Therapeutics Commences Commercial-Scale Manufacturing for Trappsol® Cyclo™
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Gainers vTv Therapeutics (NASDAQ:VTVT) shares rose 30.08% to $3.07 during Tuesday's pre-market session. The company's market cap stands at $251.7 million. Adial... 
Via Benzinga
News headline image
Cyclo Therapeutics to Present at the 2021 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
Cyclo Therapeutics Shares Move Higher On Kickstart Of Late-Stage NPC Trial With Trappsol Cyclo ↗
Cyclo Therapeutics Inc (NASDAQ: CYTH) has commenced its pivotal Phase 3 study (TransportNPC) evaluating Trappsol Cyclo for Niemann-Pick Disease Type C1 (NPC1). The... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >